Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).

To the Editor: Inhibition of factor XI or activated factor XI (XIa) should provide protection against stroke with a low risk of bleeding, given that the incidence of bleeding or adverse ...